Authors: PAZARES L KUNKA R DEMARIA D CASSIDY J ALDEN M BERANEK P KAYE S LITTLEFIELD D REILLY D DEPEE S WISSEL P TWELVES C ODWYER P

Citation: L. Pazares et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION, British Journal of Cancer, 78(10), 1998, pp. 1329-1336

Authors: KENCH S BERANEK P

Citation: S. Kench et P. Beranek, OVERVIEW OF THE SAFETY PROFILE OF TROGLITAZONE, AN INSULIN ACTION ENHANCING AGENT, Diabetologia, 40, 1997, pp. 1215-1215

Authors: GRELLIER L MUTIMER D AHMED M BROWN D BURROUGHS AK ROLLES K MCMASTER P BERANEK P KENNEDY F KIBBLER H MCPHILLIPS P ELIAS E DUSHEIKO G

Citation: L. Grellier et al., LAMIVUDINE PROPHYLAXIS AGAINST REINFECTION IN LIVER-TRANSPLANTATION FOR HEPATITIS-B CIRRHOSIS, Lancet, 348(9036), 1996, pp. 1212-1215

Authors: ODWYER P PASAREZ L KUNKA R DEMARIA D CASSIDY J KAYE S DEPEE S LITTLEFIELD D SELINGER K BERANEK P GRAHAM J WISSEL P

Citation: P. Odwyer et al., PHASE-I TRIAL OF THE TOPOISOMERASE-I INHIBITOR GG211 AS A 72-HOUR INFUSION, European journal of cancer, 31A, 1995, pp. 928-928

Authors: KUNKA RL ECKARDT JR VERWEIJ J DEPEE SP LITTLEFIELD D SELINGER KA BERANEK P COLLIS P WISSEL PS

Citation: Rl. Kunka et al., USE OF PHARMACOKINETICS AS A TOOL IN PREDICTING TOXICITY OF GG211, A NEW TOPOISOMERASE-I INHIBITOR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 175-175

Authors: TYRRELL DLJ MITCHELL MC DEMAN RA SCHALM SW MAIN J THOMAS HC FEVERY J NEVENS F BERANEK P VICARY C

Citation: Dlj. Tyrrell et al., PHASE-II TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B, Hepatology, 18(4), 1993, pp. 10000112-10000112